Bausch + Lomb (BLCO) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
4.8B
Gross Profit
2.9B
60.93%
Operating Income
188.0M
3.92%
Net Income
-305.0M
-6.37%
EPS (Diluted)
-$0.90
Balance Sheet Metrics
Total Assets
13.5B
Total Liabilities
6.9B
Shareholders Equity
6.5B
Debt to Equity
1.06
Cash Flow Metrics
Operating Cash Flow
48.0M
Free Cash Flow
-59.0M
Revenue & Profitability Trend
Bausch + Lomb Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 4.8B | 4.1B | 3.8B | 3.8B | 3.4B |
| Cost of Goods Sold | 1.9B | 1.6B | 1.5B | 1.5B | 1.3B |
| Gross Profit | 2.9B | 2.5B | 2.2B | 2.3B | 2.1B |
| Operating Expenses | 2.4B | 2.1B | 1.8B | 1.7B | 1.5B |
| Operating Income | 188.0M | 204.0M | 219.0M | 341.0M | 270.0M |
| Pre-tax Income | -234.0M | -166.0M | 73.0M | 318.0M | 290.0M |
| Income Tax | 71.0M | 82.0M | 58.0M | 125.0M | 307.0M |
| Net Income | -305.0M | -248.0M | 15.0M | 193.0M | -17.0M |
| EPS (Diluted) | -$0.90 | -$0.74 | $0.02 | $0.52 | -$0.05 |
Income Statement Trend
Bausch + Lomb Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 2.8B | 2.7B | 2.1B | 1.6B | 1.7B |
| Non-Current Assets | 10.7B | 10.7B | 9.0B | 9.2B | 9.6B |
| Total Assets | 13.5B | 13.4B | 11.1B | 10.8B | 11.3B |
| Liabilities | |||||
| Current Liabilities | 1.7B | 1.6B | 1.3B | 1.1B | 909.0M |
| Non-Current Liabilities | 5.2B | 4.9B | 2.7B | 322.0M | 369.0M |
| Total Liabilities | 6.9B | 6.5B | 4.0B | 1.4B | 1.3B |
| Equity | |||||
| Total Shareholders Equity | 6.5B | 6.9B | 7.1B | 9.4B | 10.0B |
Balance Sheet Composition
Bausch + Lomb Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -305.0M | -248.0M | 15.0M | 193.0M | -17.0M |
| Operating Cash Flow | 48.0M | 110.0M | 339.0M | 825.0M | 470.0M |
| Investing Activities | |||||
| Capital Expenditures | -291.0M | -181.0M | -175.0M | -193.0M | -253.0M |
| Investing Cash Flow | -425.0M | -2.1B | -215.0M | -214.0M | -250.0M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 178.0M | 2.1B | 81.0M | -712.0M | -232.0M |
| Free Cash Flow | -59.0M | -198.0M | 170.0M | 680.0M | 263.0M |
Cash Flow Trend
Bausch + Lomb Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-15.61
Forward P/E
11.85
Price to Book
0.78
Price to Sales
1.03
PEG Ratio
11.85
Profitability Ratios
Profit Margin
-7.50%
Operating Margin
-5.37%
Return on Equity
-5.36%
Return on Assets
0.61%
Financial Health
Current Ratio
1.56
Debt to Equity
75.07
Beta
0.56
Per Share Data
EPS (TTM)
-$1.02
Book Value per Share
$18.00
Revenue per Share
$13.71
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| blco | 5.0B | -15.61 | 0.78 | -5.36% | -7.50% | 75.07 |
| Intuitive Surgical | 184.6B | 75.42 | 10.79 | 15.96% | 28.41% | 0.00 |
| Becton, Dickinson | 50.0B | 33.87 | 1.98 | 5.89% | 7.18% | 76.34 |
| Avantor | 9.2B | 13.05 | 1.52 | 12.52% | 10.70% | 67.34 |
| Repligen | 6.9B | 511.11 | 3.49 | -1.16% | -3.53% | 34.44 |
| Stevanato | 6.4B | 44.23 | 4.52 | 9.14% | 11.16% | 27.86 |
Financial data is updated regularly. All figures are in the company's reporting currency.